A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
This is a uncontrolled, open-label, non-randomized Phase II study of oral BAY73-4506 to
evaluate the response rate of BAY73-4506 in previously untreated patients with metastatic or
unresectable renal cell cancer (RCC).